Form 4 Filing for CRISPR Therapeutics AG

This filing details a Form 4 for CRISPR Therapeutics AG, reporting ownership changes for Morrison Briggs, who is a director. On June 5, 2026, Mr. Briggs was granted 13,000 stock options with a right to buy common shares. These options have a conversion or exercise price of $51.84 and are set to expire on June 5, 2036. The options will vest in 12 equal monthly installments starting June 30, 2026, subject to continued service. Following this transaction, Mr. Briggs holds 13,000 shares. The filing was signed by Elizabeth Ryland Waldinger on June 9, 2026.